Volastra
Sarah Bettigole currently serves as Vice President and Head of Immunology and Data Science at Volastra Therapeutics, a position held since March 2020. With a strong background in immunology, previous roles at the same company include Vice President and Director of Immunology, as well as Senior Scientist. Prior experience includes a consultancy in drug development and various leadership positions at Quentis Therapeutics, Inc. and Weill Cornell Medical College, where significant research contributions were made under the mentorship of Dr. Laurie Glimcher. Sarah Bettigole completed a Ph.D. in Immunology at Harvard University, where research focused on the endoplasmic reticulum stress response in the context of the immune system and cancer, complemented by an earlier Bachelor’s degree in Biology from Tufts University.
This person is not in any teams
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.